vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and NEW JERSEY RESOURCES CORP (NJR). Click either name above to swap in a different company.
NEW JERSEY RESOURCES CORP is the larger business by last-quarter revenue ($440.9M vs $247.1M, roughly 1.8× ANI PHARMACEUTICALS INC). NEW JERSEY RESOURCES CORP runs the higher net margin — 27.8% vs 11.1%, a 16.7% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 22.8%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 0.9%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
New Jersey Resources is an energy services holding company based in Wall Township, New Jersey. It is a Fortune 1000 company, and a member of the Forbes Platinum 400. New Jersey Natural Gas is its principal subsidiary.
ANIP vs NJR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $440.9M |
| Net Profit | $27.5M | $122.5M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 40.6% |
| Net Margin | 11.1% | 27.8% |
| Revenue YoY | 29.6% | 22.8% |
| Net Profit YoY | 367.5% | -6.7% |
| EPS (diluted) | $1.14 | $1.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $440.9M | ||
| Q3 25 | $227.8M | $188.3M | ||
| Q2 25 | $211.4M | $234.8M | ||
| Q1 25 | $197.1M | $569.2M | ||
| Q4 24 | $190.6M | $359.0M | ||
| Q3 24 | $148.3M | $265.7M | ||
| Q2 24 | $138.0M | $209.9M | ||
| Q1 24 | $137.4M | $433.2M |
| Q4 25 | $27.5M | $122.5M | ||
| Q3 25 | $26.6M | $15.1M | ||
| Q2 25 | $8.5M | $-15.1M | ||
| Q1 25 | $15.7M | $204.3M | ||
| Q4 24 | $-10.3M | $131.3M | ||
| Q3 24 | $-24.2M | $91.1M | ||
| Q2 24 | $-2.3M | $-11.6M | ||
| Q1 24 | $18.2M | $120.8M |
| Q4 25 | 14.1% | 40.6% | ||
| Q3 25 | 15.9% | 21.5% | ||
| Q2 25 | 6.6% | -0.5% | ||
| Q1 25 | 13.3% | 49.2% | ||
| Q4 24 | -2.3% | 52.8% | ||
| Q3 24 | -13.8% | 55.0% | ||
| Q2 24 | 3.7% | 2.8% | ||
| Q1 24 | 14.8% | 39.3% |
| Q4 25 | 11.1% | 27.8% | ||
| Q3 25 | 11.7% | 8.0% | ||
| Q2 25 | 4.0% | -6.4% | ||
| Q1 25 | 8.0% | 35.9% | ||
| Q4 24 | -5.4% | 36.6% | ||
| Q3 24 | -16.3% | 34.3% | ||
| Q2 24 | -1.7% | -5.5% | ||
| Q1 24 | 13.2% | 27.9% |
| Q4 25 | $1.14 | $1.21 | ||
| Q3 25 | $1.13 | $0.15 | ||
| Q2 25 | $0.36 | $-0.15 | ||
| Q1 25 | $0.69 | $2.02 | ||
| Q4 24 | $-0.45 | $1.31 | ||
| Q3 24 | $-1.27 | $0.91 | ||
| Q2 24 | $-0.14 | $-0.12 | ||
| Q1 24 | $0.82 | $1.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $2.4M |
| Total DebtLower is stronger | — | $3.3B |
| Stockholders' EquityBook value | $540.7M | $2.5B |
| Total Assets | $1.4B | $7.9B |
| Debt / EquityLower = less leverage | — | 1.32× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $2.4M | ||
| Q3 25 | $262.6M | $591.0K | ||
| Q2 25 | $217.8M | $931.0K | ||
| Q1 25 | $149.8M | $83.7M | ||
| Q4 24 | $144.9M | $1.9M | ||
| Q3 24 | $145.0M | $1.0M | ||
| Q2 24 | $240.1M | $22.4M | ||
| Q1 24 | $228.6M | $5.0M |
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.3B | ||
| Q2 25 | — | $3.0B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | — | $2.8B | ||
| Q1 24 | — | $2.7B |
| Q4 25 | $540.7M | $2.5B | ||
| Q3 25 | $505.8M | $2.4B | ||
| Q2 25 | $436.8M | $2.4B | ||
| Q1 25 | $418.6M | $2.5B | ||
| Q4 24 | $403.7M | $2.3B | ||
| Q3 24 | $405.9M | $2.2B | ||
| Q2 24 | $455.8M | $2.1B | ||
| Q1 24 | $452.0M | $2.2B |
| Q4 25 | $1.4B | $7.9B | ||
| Q3 25 | $1.4B | $7.6B | ||
| Q2 25 | $1.3B | $7.3B | ||
| Q1 25 | $1.3B | $7.3B | ||
| Q4 24 | $1.3B | $7.2B | ||
| Q3 24 | $1.3B | $7.0B | ||
| Q2 24 | $920.8M | $6.8B | ||
| Q1 24 | $914.5M | $6.6B |
| Q4 25 | — | 1.32× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 1.29× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | 1.30× | ||
| Q1 24 | — | 1.25× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $26.7M |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | 0.22× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $26.7M | ||
| Q3 25 | $44.1M | $81.2M | ||
| Q2 25 | $75.8M | $-28.9M | ||
| Q1 25 | $35.0M | $423.0M | ||
| Q4 24 | $15.9M | $-9.0M | ||
| Q3 24 | $12.5M | $64.5M | ||
| Q2 24 | $17.4M | $24.3M | ||
| Q1 24 | $18.3M | $292.2M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 1.10× | 0.22× | ||
| Q3 25 | 1.66× | 5.39× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | 2.07× | ||
| Q4 24 | — | -0.07× | ||
| Q3 24 | — | 0.71× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | 2.42× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
NJR
| Residential | $284.1M | 64% |
| Commercialand Industrial | $53.4M | 12% |
| Firm Transportation | $34.7M | 8% |
| Storage And Transportation ST Segment | $28.1M | 6% |
| Home Services And Other HSO | $16.0M | 4% |
| Energy Services ES Segment | $12.8M | 3% |
| Installationand Maintenance | $6.6M | 1% |
| Electricity | $5.6M | 1% |
| Renewable Energy Certificates | $3.7M | 1% |
| Interruptibleand Offtariff | $2.4M | 1% |
